Zobrazeno 1 - 10
of 83
pro vyhledávání: '"Doua J"'
Autor:
Doua J; Janssen Research and Development, Infectious Diseases and Vaccines, Janssen Pharmaceutica, Beerse, Belgium.; European and Developing Countries Clinical Trials Partnership (EDCTP), Brussels, Belgium., Rodríguez-Baño J; Unidad Clínica de Enfermedades Infecciosas y Microbiología, Hospital Universitario Virgen Macarena, Seville, Spain.; Department of Medicine, University of Sevilla and Biomedicine Institute of Sevilla/CSIC, Seville, Spain.; CIBERINFEC, Instituto de Salud Carlos III, Madrid, Spain., Froget R; Inserm Clinical Investigation Center 1435, Dupuytren University Hospital, Limoges, France., Puranam P; Health Sciences North Research Institute, Sudbury, ON, Canada., Go O; Janssen Research and Development, Raritan, NJ, USA., Geurtsen J; Bacterial Vaccines Discovery and Early Development, Janssen Vaccines & Prevention B.V., Leiden, The Netherlands., van Rooij S; Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands., Vilken T; Laboratory of Medical Microbiology, Vaccine and Infectious Disease Institute, University of Antwerp, Antwerp, Belgium., Minoru I; Department of Respiratory Medicine, Okitama Public General Hospital, 2000, Nishi-Otsuka, Kawanishi, Yamagata, Japan., Yasumori I; Department of General Internal Medicine, National Hospital Organization Nagasaki Medical Center, Nagasaki, Japan., Spiessens B; Janssen Research and Development, Infectious Diseases and Vaccines, Janssen Pharmaceutica, Beerse, Belgium., Tacconelli E; Division of Infectious Diseases, Department of Diagnostic and Public Health, University of Verona, Verona, Italy., Biehl LM; Department I of Internal Medicine, Faculty of Medicine and University Hospital of Cologne, University of Cologne, 50924, Cologne, Germany.; German Centre for Infection Research, Partner Site Bonn-Cologne, Cologne, Germany., Thaden JT; Department of Medicine, Division of Infectious Diseases, Duke University School of Medicine, Durham, NC, USA., Sarnecki M; Janssen Vaccines, Branch of Cilag GmbH International, Bern, Switzerland. sarnecki.michal@gmail.com., Goossens H; Laboratory of Medical Microbiology, Vaccine and Infectious Disease Institute, University of Antwerp, Antwerp, Belgium., Poolman J; Bacterial Vaccines Discovery and Early Development, Janssen Vaccines & Prevention B.V., Leiden, The Netherlands., Bonten M; Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands., Ekkelenkamp M; Department of Medical Microbiology, University Medical Center Utrecht, Utrecht, The Netherlands.
Publikováno v:
Infection [Infection] 2024 Jun; Vol. 52 (3), pp. 1073-1085. Date of Electronic Publication: 2024 Jan 25.
Autor:
Arconada Nuin E; Laboratory of Medical Microbiology, Vaccine & Infectious Disease Institute, University of Antwerp, Antwerp, Belgium., Vilken T; Laboratory of Medical Microbiology, Vaccine & Infectious Disease Institute, University of Antwerp, Antwerp, Belgium., Xavier BB; Laboratory of Medical Microbiology, Vaccine & Infectious Disease Institute, University of Antwerp, Antwerp, Belgium.; Department of Medical Microbiology and Infection Control, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands., Doua J; Janssen Research & Development, Infectious Diseases & Vaccines, Janssen Pharmaceutica, Beerse, Belgium., Morrow B; Janssen Research & Development, Raritan, NJ, USA., Geurtsen J; Bacterial Vaccines Discovery & Early Development, Janssen Vaccines & Prevention B.V., Leiden, The Netherlands., Go O; Janssen Research & Development, Raritan, NJ, USA., Spiessens B; Janssen Research & Development, Infectious Diseases & Vaccines, Janssen Pharmaceutica, Beerse, Belgium., Sarnecki M; Janssen Vaccines, Branch of Cilag GmbH International, Bern, Switzerland., Poolman J; Bacterial Vaccines Discovery & Early Development, Janssen Vaccines & Prevention B.V., Leiden, The Netherlands., Bonten M; Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.; ECRAID, Utrecht, The Netherlands., Ekkelenkamp M; Department of Medical Microbiology, University Medical Center Utrecht, Utrecht, The Netherlands., Lammens C; Laboratory of Medical Microbiology, Vaccine & Infectious Disease Institute, University of Antwerp, Antwerp, Belgium., Goossens H; Laboratory of Medical Microbiology, Vaccine & Infectious Disease Institute, University of Antwerp, Antwerp, Belgium., Glupczynski Y; Laboratory of Medical Microbiology, Vaccine & Infectious Disease Institute, University of Antwerp, Antwerp, Belgium., Van Puyvelde S; Laboratory of Medical Microbiology, Vaccine & Infectious Disease Institute, University of Antwerp, Antwerp, Belgium.; Cambridge Institute of Therapeutic Immunology and Infectious Disease, University of Cambridge School of Clinical Medicine, Cambridge Biomedical Campus, Cambridge CB2 0AW, UK.
Publikováno v:
The Journal of antimicrobial chemotherapy [J Antimicrob Chemother] 2024 Sep 03; Vol. 79 (9), pp. 2142-2151.
Autor:
Goldstein N; Janssen Vaccines & Prevention B.V, Leiden, The Netherlands., McLean C; Janssen Vaccines & Prevention B.V, Leiden, The Netherlands., Gaddah A; Janssen Research & Development, Beerse, Belgium., Doua J; Janssen Research & Development, Beerse, Belgium., Keshinro B; Janssen Vaccines & Prevention B.V, Leiden, The Netherlands., Bus-Jacobs L; Janssen Vaccines & Prevention B.V, Leiden, The Netherlands., Hendriks J; Janssen Vaccines & Prevention B.V, Leiden, The Netherlands., Luhn K; Janssen Vaccines & Prevention B.V, Leiden, The Netherlands., Robinson C; Janssen Vaccines & Prevention B.V, Leiden, The Netherlands., Douoguih M; Janssen Vaccines & Prevention B.V, Leiden, The Netherlands.
Publikováno v:
Human vaccines & immunotherapeutics [Hum Vaccin Immunother] 2024 Dec 31; Vol. 20 (1), pp. 2327747. Date of Electronic Publication: 2024 Mar 24.
Autor:
Doua J; Janssen Research & Development, Beerse, Belgium., Ekkelenkamp M; Department of Medical Microbiology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands., Verheij T; Julius Center for Health Sciences and Primary Care, University Medical Center, Utrecht University, Utrecht, the Netherlands., Go O; Janssen Research & Development, Raritan, NJ, USA., Ruhmel S; Janssen Research & Development, Titusville, NJ, USA., Leathers K; Duke University School of Medicine, Durham, NC, USA., Spiessens B; Janssen Research & Development, Beerse, Belgium., van Rooij S; Julius Center for Health Sciences and Primary Care, University Medical Center, Utrecht University, Utrecht, the Netherlands., Fowler VG Jr; Department of Medicine, Duke University Medical Center Durham, Durham, NC, USA.; Duke Clinical Research Institute, Durham, NC, USA., Geurtsen J; Bacterial Vaccines Discovery and Early Development, Janssen Vaccines & Prevention B.V, Leiden, the Netherlands., Dolor R; Duke University School of Medicine, Durham, NC, USA., Sarnecki M; Janssen Vaccines, Branch of Cilag GmbH International, Bern, Switzerland. sarnecki.michal@gmail.com.; IQVIA, Research Triangle Park, Durham, NC, USA. sarnecki.michal@gmail.com., Chatterjee R; Duke University School of Medicine, Durham, NC, USA., Poolman J; Bacterial Vaccines Discovery and Early Development, Janssen Vaccines & Prevention B.V, Leiden, the Netherlands., Bonten M; Julius Center for Health Sciences and Primary Care, University Medical Center, Utrecht University, Utrecht, the Netherlands.
Publikováno v:
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology [Eur J Clin Microbiol Infect Dis] 2024 Mar; Vol. 43 (3), pp. 541-550. Date of Electronic Publication: 2024 Jan 18.
Autor:
Fierro CA; Johnson County Clin-Trials, Lenexa, Kansas, USA., Sarnecki M; Infectious Diseases and Vaccines, Janssen Research and Development, Janssen Vaccines, Bern, Switzerland., Doua J; Infectious Diseases and Vaccines, Janssen Research and Development, Janssen Pharmaceutica, Beerse, Belgium., Spiessens B; Infectious Diseases and Vaccines, Janssen Research and Development, Janssen Pharmaceutica, Beerse, Belgium., Go O; Janssen Research and Development, Raritan, New Jersey, USA., Davies TA; Janssen Research and Development, Raritan, New Jersey, USA., van den Dobbelsteen G; Bacterial Vaccines Discovery and Early Development, Janssen Vaccines and Prevention B.V., Leiden, The Netherlands., Poolman J; Bacterial Vaccines Discovery and Early Development, Janssen Vaccines and Prevention B.V., Leiden, The Netherlands., Abbanat D; Janssen Research and Development, Raritan, New Jersey, USA., Haazen W; Infectious Diseases and Vaccines, Janssen Research and Development, Janssen Pharmaceutica, Beerse, Belgium.
Publikováno v:
Open forum infectious diseases [Open Forum Infect Dis] 2023 Aug 11; Vol. 10 (8), pp. ofad417. Date of Electronic Publication: 2023 Aug 11 (Print Publication: 2023).
Autor:
Doua, J., Rodríguez-Baño, J., Vallejo, C., Puranam, P., Go, O., Geurtsen, J., van Rooij, S., Vilken, T., Minoru, I., Yasumori, I., Spiessens, B., Tacconelli, E., Biehl, L., Thaden, J., Sarnecki, M., Goossens, H., Poolman, J., Bonten, M., Ekkelenkamp, M.
Publikováno v:
In International Journal of Infectious Diseases May 2023 130 Supplement 2:S109-S110
Autor:
Fierro, C., Sarnecki, M., Doua, J., Spiessens, B., Go, O., Davies, T., van den Dobbelsteen, G., Poolman, J., Abbanat, D., Haazen, W.
Publikováno v:
In International Journal of Infectious Diseases May 2023 130 Supplement 2:S114-S114
Autor:
Doua J; Janssen Research & Development, Infectious Diseases & Vaccines, Janssen Pharmaceutica, Beerse, Belgium., Geurtsen J; Bacterial Vaccines Discovery and Early Development, Janssen Vaccines & Prevention B.V., Leiden, The Netherlands., Rodriguez-Baño J; Unidad Clínica de Enfermedades Infecciosas y Microbiología, Hospital Universitario Virgen Macarena, Seville, Spain.; Department of Medicine, University of Sevilla, Seville, Spain.; Biomedicine Institute of Sevilla/CSIC, Seville, Spain.; CIBER de Enfermedades Infecciosas, Instituto de Salud Carlos III, Madrid, Spain., Cornely OA; Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Excellence Center for Medical Mycology (ECMM), University of Cologne, Cologne, Germany.; Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Cologne, Germany.; Clinical Trials Centre Cologne (ZKS Köln), University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.; German Centre for Infection Research (DZIF), Partner Site Bonn-Cologne, Cologne, Germany., Go O; Janssen Research & Development, Raritan, New Jersey, USA., Gomila-Grange A; Infectious Diseases Department, Hospital Universitari de Bellvitge, Carrer de la Feixa Llarga, s/n, 08907 L'Hospitalet de Llobregat, Barcelona, Spain.; Infectious Diseases Department, Hospital Parc Taulí de Sabadell, Parc Tauli, Barcelona, Spain., Kirby A; Leeds Institute of Medical Research, The University of Leeds, Old Medical School, Leeds General Infirmary, Leeds, West Yorkshire, United Kingdom., Hermans P; Julius Center for Health Sciences and Primary Care University Medical Center, Utrecht University, Utrecht, The Netherlands., Gori A; Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy., Zuccaro V; Infectious Diseases Department, IRCCS Policlinico San Matteo Foundation, University of Pavia, Pavia, Lombardy, Italy., Gravenstein S; Department of Medicine, Alpert Medical School of Brown University, Providence, Rhode Island, USA., Bonten M; Julius Center for Health Sciences and Primary Care, University Medical Center, Utrecht, The Netherlands., Poolman J; Bacterial Vaccines Discovery and Early Development, Janssen Vaccines & Prevention B.V., Leiden, The Netherlands., Sarnecki M; Clinical Development, Janssen Vaccines, Bern, Switzerland.
Publikováno v:
Open forum infectious diseases [Open Forum Infect Dis] 2023 Jan 27; Vol. 10 (2), pp. ofad026. Date of Electronic Publication: 2023 Jan 27 (Print Publication: 2023).
Autor:
Fortin SP; Janssen Research & Development, Observational Health Data Analytics, Raritan, New Jersey, USA., Hernandez Pastor L; Janssen Research & Development, Infectious Diseases and Vaccines, Beerse, Belgium., Doua J; Janssen Research & Development, Infectious Diseases and Vaccines, Beerse, Belgium., Sarnecki M; Janssen Vaccines, Branch of Cilag GmbH International, Bern, Switzerland., Swerdel J; Janssen Research & Development, Observational Health Data Analytics, Raritan, New Jersey, USA., Colasurdo J; Janssen Research & Development, Epidemiology, Raritan, New Jersey, USA., Geurtsen J; Janssen Vaccines & Prevention, Bacterial Vaccines Research & Early Development, CN, Leiden, Netherlands.
Publikováno v:
Pharmacoepidemiology and drug safety [Pharmacoepidemiol Drug Saf] 2022 Sep; Vol. 31 (9), pp. 983-991. Date of Electronic Publication: 2022 Jul 10.
Autor:
Fortin SP; Janssen Research & Development, Observational Health Data Analytics, Raritan, New Jersey, USA., Swerdel J; Janssen Research & Development, Observational Health Data Analytics, Raritan, New Jersey, USA., Sarnecki M; Janssen Vaccines, Branch of Cilag GmbH International, Bern, Switzerland., Doua J; Janssen Research & Development, Infectious Diseases and Vaccines, Beerse, Belgium., Colasurdo J; Janssen Research & Development, Epidemiology, Raritan, New Jersey, USA., Geurtsen J; Janssen Vaccines & Prevention, Bacterial Vaccines Research & Early Development, Leiden, Netherlands.
Publikováno v:
Pharmacoepidemiology and drug safety [Pharmacoepidemiol Drug Saf] 2022 Sep; Vol. 31 (9), pp. 953-962. Date of Electronic Publication: 2022 Jul 04.